Cargando…
Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy
INTRODUCTION: Targetable alterations such as BRAFV600E mutation and NTRK fusion are enriched in microsatellite instability-high (MSI-H) colorectal cancer (CRC). MSI-H with targetable alterations (MSI-H altered) might present unique opportunities for both targeted therapy and immunotherapy. We system...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870311/ https://www.ncbi.nlm.nih.gov/pubmed/36700211 http://dx.doi.org/10.3389/fimmu.2022.974793 |
_version_ | 1784876949272788992 |
---|---|
author | Hua, Hanju He, Wenguang Chen, Nan He, Yinjun Wu, Guosheng Ye, Feng Zhou, Xile Li, Yandong Ding, Yongfeng Zhong, Weixiang Teng, Lisong Jiang, Weiqin Sheng, Qinsong |
author_facet | Hua, Hanju He, Wenguang Chen, Nan He, Yinjun Wu, Guosheng Ye, Feng Zhou, Xile Li, Yandong Ding, Yongfeng Zhong, Weixiang Teng, Lisong Jiang, Weiqin Sheng, Qinsong |
author_sort | Hua, Hanju |
collection | PubMed |
description | INTRODUCTION: Targetable alterations such as BRAFV600E mutation and NTRK fusion are enriched in microsatellite instability-high (MSI-H) colorectal cancer (CRC). MSI-H with targetable alterations (MSI-H altered) might present unique opportunities for both targeted therapy and immunotherapy. We systematically evaluated the molecular characteristics and immune-related features of MSI-H altered and MSI-H without targetable alterations (MSI-H wt) CRC patients in our study. METHODS: Among 1938 continuously enrolled CRC patients, 126 patients with MSI-H status (6.50%) were included in this retrospective study. Genomic and transcriptomic data were investigated by next-generation sequencing (NGS) and gene expression profiling (GEP), respectively. RESULTS: BRAFV600E, NTRK1, and FGFR2 mutations were the most frequent targetable alterations in MSI-H CRC patients. The MSI-H altered phenotype was significantly associated with older age (p< 0.001), right side (p=0.024) and females (p= 0.036). No lynch syndrome (LS) patients were identified in MSI-H altered group. The tumor mutational burden (TMB), and tumor neoantigen burden (TNB) of MSI-H altered and wt subgroups were comparable (p<0.05). Subsequently, transcriptomic study analysis further revealed MSI-H altered CRC patients were linked to an immune-active tumor microenvironment with higher levels of Teff IFN-gamma, CYT, and MERCK 18 signatures, and lower levels of the IPRES gene signature, EMT and TGF Beta signatures. In addition, case study supported MSI-H CRC patient harboring targetable alterations might also achieved a long-term disease-free survival benefit from immunotherapy. DISCUSSION: Our study preliminary revealed MSI-H altered as a novel subtype of MSI-H CRC patients with unique molecular signatures and immune-active tumor microenvironment. Given the accessibility of immune checkpoint inhibitors (ICIs) treatment, our results might provide clinical evidence for immunotherapy in MSI-H CRC patients with targetable alterations. |
format | Online Article Text |
id | pubmed-9870311 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98703112023-01-24 Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy Hua, Hanju He, Wenguang Chen, Nan He, Yinjun Wu, Guosheng Ye, Feng Zhou, Xile Li, Yandong Ding, Yongfeng Zhong, Weixiang Teng, Lisong Jiang, Weiqin Sheng, Qinsong Front Immunol Immunology INTRODUCTION: Targetable alterations such as BRAFV600E mutation and NTRK fusion are enriched in microsatellite instability-high (MSI-H) colorectal cancer (CRC). MSI-H with targetable alterations (MSI-H altered) might present unique opportunities for both targeted therapy and immunotherapy. We systematically evaluated the molecular characteristics and immune-related features of MSI-H altered and MSI-H without targetable alterations (MSI-H wt) CRC patients in our study. METHODS: Among 1938 continuously enrolled CRC patients, 126 patients with MSI-H status (6.50%) were included in this retrospective study. Genomic and transcriptomic data were investigated by next-generation sequencing (NGS) and gene expression profiling (GEP), respectively. RESULTS: BRAFV600E, NTRK1, and FGFR2 mutations were the most frequent targetable alterations in MSI-H CRC patients. The MSI-H altered phenotype was significantly associated with older age (p< 0.001), right side (p=0.024) and females (p= 0.036). No lynch syndrome (LS) patients were identified in MSI-H altered group. The tumor mutational burden (TMB), and tumor neoantigen burden (TNB) of MSI-H altered and wt subgroups were comparable (p<0.05). Subsequently, transcriptomic study analysis further revealed MSI-H altered CRC patients were linked to an immune-active tumor microenvironment with higher levels of Teff IFN-gamma, CYT, and MERCK 18 signatures, and lower levels of the IPRES gene signature, EMT and TGF Beta signatures. In addition, case study supported MSI-H CRC patient harboring targetable alterations might also achieved a long-term disease-free survival benefit from immunotherapy. DISCUSSION: Our study preliminary revealed MSI-H altered as a novel subtype of MSI-H CRC patients with unique molecular signatures and immune-active tumor microenvironment. Given the accessibility of immune checkpoint inhibitors (ICIs) treatment, our results might provide clinical evidence for immunotherapy in MSI-H CRC patients with targetable alterations. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9870311/ /pubmed/36700211 http://dx.doi.org/10.3389/fimmu.2022.974793 Text en Copyright © 2023 Hua, He, Chen, He, Wu, Ye, Zhou, Li, Ding, Zhong, Teng, Jiang and Sheng https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Hua, Hanju He, Wenguang Chen, Nan He, Yinjun Wu, Guosheng Ye, Feng Zhou, Xile Li, Yandong Ding, Yongfeng Zhong, Weixiang Teng, Lisong Jiang, Weiqin Sheng, Qinsong Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy |
title | Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy |
title_full | Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy |
title_fullStr | Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy |
title_full_unstemmed | Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy |
title_short | Genomic and transcriptomic analysis of MSI-H colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy |
title_sort | genomic and transcriptomic analysis of msi-h colorectal cancer patients with targetable alterations identifies clinical implications for immunotherapy |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870311/ https://www.ncbi.nlm.nih.gov/pubmed/36700211 http://dx.doi.org/10.3389/fimmu.2022.974793 |
work_keys_str_mv | AT huahanju genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT hewenguang genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT chennan genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT heyinjun genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT wuguosheng genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT yefeng genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT zhouxile genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT liyandong genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT dingyongfeng genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT zhongweixiang genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT tenglisong genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT jiangweiqin genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy AT shengqinsong genomicandtranscriptomicanalysisofmsihcolorectalcancerpatientswithtargetablealterationsidentifiesclinicalimplicationsforimmunotherapy |